

Screening Libraries

Product Data Sheet

Emicizumab

Cat. No.: HY-P9940 CAS No.: 1610943-06-0 Target: Factor VIII

Metabolic Enzyme/Protease Pathway:

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Proteins

BIOLOGICAL ACTIVITY

es			

Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research^[1].

In Vivo

Emicizumab (1.5-10 mg/kg, IV, 24 hours before tail-clip bleeding) partially corrects blood loss in a hemophilia A bleeding model, with an FVIII equivalence of 9 $U/dL^{[1]}$.

Emicizumab (3 mg/kg, IV) provides additive hemostatic activity when given in combination with low-dose FVIII (10 U/dL)^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	FVIII-deficient mice $^{[1]}$		
Dosage:	1.5-10 mg/kg		
Administration:	IV, 24 hours before tail-clip bleeding was performed		
Result:	Significantly reduced blood loss in a tail-clip-bleeding model using FVIII-deficient mice.		

REFERENCES

[1]. Ferrière S, et al. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood. 2020 Aug 6;136(6):740-748.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 1 of 1